Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years
Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months vs. standard of care
Recommendation based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
Combination shows consistent benefit across prespecified post-progression outcomes
The company has received five final approvals
The receipt of this permission paves way for the launch of Osimertinib 40mg/80mg film coated tablets in India.
Subscribe To Our Newsletter & Stay Updated
